

5'-GCAGTGGGCGCCCACAGTACTTGAACGTAACG—Bio 3'-CGTCACCGCGCGGGTGTCATGAACTTGCATTGC

Fig. 3

peptide 1: GGGQWLGTWEWYGPK (10)
2: YEKISVEGIKDVRVR (9)
3: NVSIEGVLKYYRGLR (6)
4: RSCGLDYEGYWLKLK (13)
5: SRWLEEEVSRLLLLR (6)
6: GEALDRFEREMKLMR (1)




Fig. 4




Fig. 5

	CIPE CO	
REFERENCE	Ta Praumon E	1.

	E21D			- Zif12
MRLWR MRGWK MRKWR MRKWR MRKWR MRKWR		MRKWR MRKWR MRKWR MRKWR	MRKWR MRKWR MRKWR MRKWR MRKWR MRKWR	EYLES MRKWR
EEVSR EEVSR EEVSR EEVSR EEVSR EEVSR			EYLES EYLES EYLES EYLES EYLES EYLES	EYLES
FRWLE FRWLE FRWLE SRWLE SRWLE SRWLE SRWLE	SRWLE SRWLE SRWLE SRWLE	SRWLE SRWLE SRWLE SRWLE SRWLE	OPWLT PPWLI PPWLK PAWLT PAWLA WAWLD PPWLK	
Step 1 (Cycle 9)	Step 2	(case)	Step 3 (Cycle 6)	peptide 5*
	E21D			- zif12 - zif12
HPKMK PAKIR VPKSR VPRLK APKLR HAKIR VVKMR	<b>VPKQR</b> VPKQR VPKQR	VPKQR VPKQR VPKQR VPKQR VPKQR	VPKMR VPKMR VRKLR VRKLR VRKLR	VPKMR VRKLR
	(i) V[5]			
LGTWE LGTWE LGTWE LGTWE LGTWE LGTWE LGTWE	LGTWI		LLINYV LLINYV LLINYV LLINYV LLINYV	LLNYV
GGGOW LGTWE GGGOW LGTWE GGGOW LGTWE GGGOW LGTWE GGGOW LGTWE GGGOW LGTWE				peptide 1* HPMNN LLNYV VPKMR - peptide 1* ENYEK LLNYV VRKLR - (variant)
	Step 1 FRWLE EEVSR MRGWK (Cycle 9) SRWLE EEVSR MRKWR	E21D	E21D	E21D

peptide 1 GGGQW LGTWE WYGPK - Zifl2



AIPI: PYACPYRS C D R R F S R & D & D T R K T R I H T GLT1: E T D C D M G G C S Q E P D & Q E Q D V R H T N SEH I GLJ2: K T V C D G G C SKELRUY K A Q Y M D V N M K H H T SMII: T T E C T D B C C T X T F F K N V N T W C H T Q T X L

Figure 7





Fig 8



F19 9